1. Academic Validation
  2. The evaluation of isatin analogues as inhibitors of monoamine oxidase

The evaluation of isatin analogues as inhibitors of monoamine oxidase

  • Chem Biol Drug Des. 2023 Nov;102(5):1067-1074. doi: 10.1111/cbdd.14304.
Izak F Prinsloo 1 Jacobus P Petzer 1 Theunis T Cloete 1 Anél Petzer 1
Affiliations

Affiliation

  • 1 Pharmaceutical Chemistry, School of Pharmacy and Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, South Africa.
Abstract

The small molecule, isatin, is a well-known reversible inhibitor of the Monoamine Oxidase (MAO) Enzymes with IC50 values of 12.3 and 4.86 μM for MAO-A and MAO-B, respectively. While the interaction of isatin with MAO-B has been characterized, only a few studies have explored structure-activity relationships (SARs) of MAO inhibition by isatin analogues. The current study therefore evaluated a series of 14 isatin analogues as in vitro inhibitors of human MAO-A and MAO-B. The results indicated good potency MAO inhibition for some isatin analogues with five compounds exhibiting IC50 < 1 μM. 4-Chloroisatin (1b) and 5-bromoisatin (1f) were the most potent inhibitors with IC50 values of 0.812 and 0.125 μM for MAO-A and MAO-B, respectively. These compounds were also found to be competitive inhibitors of MAO-A and MAO-B with Ki values of 0.311 and 0.033 μM, respectively. Among the SARs, it was interesting to note that C5-substitution was particularly beneficial for MAO-B inhibition. MAO inhibitors are established drugs for the treatment of neuropsychiatric and neurodegenerative disorders, while potential new roles in prostate Cancer and Cardiovascular Disease are being investigated.

Keywords

competitive; inhibition; isatin; monoamine oxidase; structure-activity relationship.

Figures
Products